• Professor Zhu Biao: Impact of Single-Tablet HIV Medications B/F/TAF and E/C/F/TAF on Lipid Metabolism

    AIDS remains a significant global health concern, but recent advancements in medical technology have shifted the treatment of HIV-infected individuals toward a chronic disease management approach. Ensuring treatment safety and adherence is a critical challenge within this context. Currently, two single-tablet regimens, Biktarvy (B/F/TAF) and Descovy (E/C/F/TAF), are widely used globally, including in China, for…

  • Professor Lv Wei: An All-Encompassing Interpretation of Clinical Diagnosis and Treatment Strategies for Late-Diagnosed HIV Patients

    This article features an interview with Professor Lv Wei, offering a comprehensive analysis of the clinical diagnosis and treatment strategies for late-presenting HIV patients. This group is a significant challenge in China’s HIV/AIDS prevention and treatment efforts due to their higher hospitalization and transmission rates, heavier economic burdens, and poorer long-term prognosis.

  • Pay attention to the comorbidities of the heart, lungs, and metabolic system in HIV infected individuals

    Anti retroviral therapy (ART) significantly improves the life expectancy of HIV infected individuals. However, in recent years, the incidence rate of cardiovascular diseases and other complications related to obesity, type 2 diabetes, and metabolic syndrome (namely, abdominal obesity, hypertension, elevated triglyceride levels, dyslipidemia, and changes in blood glucose levels) has gradually increased among HIV infected…

  • Exposure and Response to ART Drugs in Obese HIV-Infected Individuals

    This article is an interview transcript from the 19th European AIDS Conference (EACS 2023) featuring Dr. Mattia Berton from the University Hospital Basel, Switzerland. The focus of the interview is on the study of antiretroviral therapy (ART) drug exposure and response in obese HIV-infected individuals.

  • CVD risks in women living with HIV

    Hi there. My name is Chris Longenecker. I’m a cardiologist at the University of Washington in Seattle, Washington, USA. I specialize in the care of people living with HIV infection. For many years I’ve run a clinic focused on cardiovascular disease management and prevention of cardiovascular disease for people living with HIV, first in Cleveland,…

  • Advances and Challenges in the Use of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) for HIV

    With continuous progress in HIV treatment, the mortality rate has significantly decreased, and new infections have stabilized. However, there is still a gap from the 2020 targets set by the United Nations Programme on HIV/AIDS. To control new HIV infections, a comprehensive use of behavioral and biomedical methods, including antiviral drugs for pre-exposure prophylaxis (PrEP)…

  • Progress and Challenges in the Field of HIV/AIDS – The 19th EACS Conference Concludes Successfully

    The 19th European AIDS Conference (EACS 2023), a highly anticipated event in the field of HIV/AIDS, was held grandly in Warsaw, Poland, from October 18 to 20, 2023. The conference provided a robust platform for medical professionals and researchers in the HIV/AIDS field, facilitating a comprehensive and multi-faceted discussion on urgent issues in combating HIV/AIDS.…

  • What to start with? A review of current guidelines (EACS, WHO, DHHS)

    Hello. My name is Cristiana Oprea. I’m an infectious disease and HIV clinician at Victor Babes Hospital for infectious and tropical diseases in Bucharest, and also an associate professor at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. I am part of the European AIDS Clinical Society governing board since 2014, and also…